GSK and Theravance have announced results for two Phase 3 studies of its ICS/LABA combo DPI Relovair for the treatment of COPD. The product combines fluticasone furoate and vilanterol.
The companies said that the studies demonstrated statistically significant change in 0-4 hour weighted mean FEV1 and trough FEV1 for patients treated with Relovair compared with placebo, for vilanterol compared to placebo, and for Relovair compared to fluticasone alone. However, Relovair compared to vilanterol alone failed to reach statistical significance in improvement on trough FEVI.
Senior Vice President of GSK Darrell Baker commented: “Successful completion of these two studies is an important milestone in the development of Relovair for COPD. These data will be reviewed together with the larger 12 month exacerbation studies still underway, to develop a complete evaluation of Relovair in treating patients with COPD.”
Read the GSK/Theravance press release.
